Please assess the completion status of the following clinical trial:

Trial Title: Safety of Fondaparinux as Routine VTE Prophylaxis in Medical ICU Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Ability or legally authorized representative (LAR) to provide informed consent~2. Adult who has not had surgery within 10 days, admitted to the Sentara Norfolk General Hospital ICU Medical Teaching Services for any reason.~Exclusion Criteria:~1. Active or suspected bleeding~2. Platelet count less than 100,000 per microliter (mm3) of blood~3. Thrombolytic or anticoagulant treatment (including any doses of prophylactic UFH, LMWH or fondaparinux) during the current hospitalization~4. Initial estimated CLcr \< 30 ml/min as determined by the Cockcroft-Gault equation~5. Initial labs indicative or suggestive of rapidly rising serum Creatinine (\>1 mg/dL/day)~6. Pregnancy (for medicolegal considerations)~7. Patients with or expecting to require an epidural catheter~8. Patients who are expected to have an immediate (within 24h) need for surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 89 Years
- Healthy Volunteers: f

Study Arms:
- Fondaparinux (Type: EXPERIMENTAL): Fondaparinux treatment - one standard of care option
- 2 (Type: ACTIVE_COMPARATOR): Enoxaparin

Based on this trial design, predict the completion outcome and termination type (if applicable).